Biologic therapies have revolutionized the treatment of chronic conditions such as autoimmune and inflammatory diseases. Among these therapies, adalimumab—a TNF-α inhibitor—has emerged as a frontrunner. However, its high cost has driven the development of biosimilars, offering cost-effective alternatives without compromising on efficacy. This article explores the impact,...